Christian B Allan

US Patent:

7294336, Nov 13, 2007

Filed:

Feb 24, 2006

Appl. No.:

11/362267

Inventors:

Cynthia N. Oliver - N. Potomac MD, US
Erica Shane - McLean VA, US
Benjamin S. Isaacs - Andover MA, US
Christian B. Allan - Brookeville MD, US
Stephen T. Chang - Frederick MD, US

Assignee:

MedImmune, Inc. - Gaithersburg MD

International Classification:

A61K 39/395
A61K 39/42

US Classification:

4241301, 4241411, 4241471, 4241591

Abstract:

The present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.

US Patent:

7425618, Sep 16, 2008

Filed:

Jun 13, 2003

Appl. No.:

10/461863

Inventors:

Cynthia N. Oliver - N. Potomac MD, US
Christian B. Allan - Brookeville MD, US
Stephen T. Chang - Frederick MD, US

Assignee:

Medimmune, Inc. - Gaithersburg MD

International Classification:

C12P 21/08

US Classification:

5303871, 5303881, 5303891, 4241591

Abstract:

The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention.

US Patent:

7585504, Sep 8, 2009

Filed:

Oct 21, 2005

Appl. No.:

11/254679

Inventors:

Herren Wu - Boyds MD, US
Christian B. Allan - Brookeville MD, US
Changshou Gao - Potomac MD, US
Ling-Ling An - Boyds MD, US
Peter Kiener - Potomac MD, US
Anthony Coyle - Washington DC, US

Assignee:

MedImmune, LLC - Gaithersburg MD

International Classification:

A61K 39/395

US Classification:

4241421, 4241581, 53038815, 53038823

Abstract:

Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.

US Patent:

7691379, Apr 6, 2010

Filed:

Apr 12, 2005

Appl. No.:

11/105268

Inventors:

Christian B. Allan - Brookeville MD, US

Assignee:

Medimmune, LLC - Gaithersburg MD

International Classification:

A61K 39/395
C07K 16/00

US Classification:

4241451, 53038823

Abstract:

The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to an IL-9 polypeptide, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to an IL-9 polypeptide, which formulations are substantially free of surfactants, sugars, sugar alcohols, amino acids other than histidine (preferably with pKa values of less than 5 and above 7), and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating a disease or disorder associated with or characterized by aberrant expression and/or activity of an IL-9 polypeptide, a disease or disorder associated with or characterized by aberrant expression and/or activity of the IL-9R or one or more subunits thereof, an autoimmune disease, an inflammatory disease, a proliferative disease, or an infection (preferably, a respiratory infection), or one or more symptoms thereof, utilizing the liquid formulations of the present invention.

US Patent:

7785592, Aug 31, 2010

Filed:

Oct 1, 2007

Appl. No.:

11/906543

Inventors:

Cynthia N. Oliver - North Potomac MD, US
Erica Shane - McLean VA, US
Benjamin S. Isaacs - Andover MA, US
Christian B. Allan - Brookeville MD, US
Stephen T. Chang - Frederick MD, US

Assignee:

MedImmune, LLC - Gaithersburg MD

International Classification:

A61K 39/395
A61K 39/40
A61K 39/42
C07K 16/00

US Classification:

4241331, 4241421, 4241471, 4241591, 5303871, 5303873, 5303881, 53038815, 5303883

Abstract:

The present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.

US Patent:

8007793, Aug 30, 2011

Filed:

Jun 16, 2010

Appl. No.:

12/817097

Inventors:

Cynthia N. Oliver - North Potomac MD, US
Erica Shane - McLean VA, US
Benjamin S. Isaacs - Andover MA, US
Christian B. Allan - Brookeville MD, US
Stephen T. Chang - Frederick MD, US

Assignee:

MedImmune, LLC - Gaithersburg MD

International Classification:

A61K 39/395
A61K 39/42

US Classification:

4241301, 4241411, 4241471, 4241591

Abstract:

The present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.

US Patent:

8153131, Apr 10, 2012

Filed:

Aug 3, 2009

Appl. No.:

12/534217

Inventors:

Herren Wu - Boyds MD, US
Christian Allan - Brookeville MD, US
Changshou Gao - Potomac MD, US
Ling-Ling An - Boyds MD, US
Peter Kiener - Potomac MD, US
Anthony Coyle - Washington DC, US

Assignee:

MedImmune, LLC - Gaithersburg MD

International Classification:

A61K 39/395

US Classification:

4241451, 53038823

Abstract:

Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.

US Patent:

8309690, Nov 13, 2012

Filed:

Jun 30, 2006

Appl. No.:

11/993680

Inventors:

Christian Allan - Brookeville MD, US
Herren Wu - Boyds MD, US
Jeffrey Swers - Rockville MD, US
William Dall'Acqua - Gaithersburg MD, US

Assignee:

MedImmune, LLC - Gaithersburg MD

International Classification:

C07K 16/00

US Classification:

5303873, 4241301

Abstract:

The invention provides method for therapeutic protein drug development that incorporates therapeutic and/or formulation and/or manufacturing considerations in the early screening process. The approach involves screening a plurality of different variants of a domain that have been determined to have the desired therapeutic property to identify one or more variants that have desired therapeutic and/or formulation characteristics, and constructing the full multidomain proteins using the identified domain variants. The present invention also provides a method for determining the shelf life of multidomain proteins in formulations. The method comprises determining a thermal denaturation and/or renaturation curve of a domain of the protein whose unfolding leads to aggregation of the protein in a solution. The method evaluates the shelf life of the multidomain protein based on the denaturation/renaturation curve. The invention also provides methods for engineering multidomain proteins to improve their therapeutic and/or formulation characteristics.